Earnings Recaps

Browse reported earnings of the most popular stocks

Apr 2, 2026 Apr 1, 2026 Mar 31, 2026 Mar 30, 2026 Mar 26, 2026 Mar 25, 2026 Mar 20, 2026 Mar 19, 2026 Mar 18, 2026 Mar 17, 2026 Mar 16, 2026 Mar 13, 2026 Mar 12, 2026 Mar 11, 2026 Mar 9, 2026 Mar 7, 2026 Mar 6, 2026 Mar 5, 2026 Mar 4, 2026 Mar 3, 2026 Mar 2, 2026 Feb 28, 2026 Feb 27, 2026 Feb 26, 2026 Feb 25, 2026 Feb 24, 2026 Feb 23, 2026 Feb 21, 2026 Feb 20, 2026 Feb 19, 2026 Feb 18, 2026 Feb 17, 2026 Feb 14, 2026 Feb 13, 2026 Feb 12, 2026 Feb 11, 2026 Feb 10, 2026 Feb 9, 2026 Feb 7, 2026 Feb 6, 2026 Feb 5, 2026 Feb 4, 2026 Feb 3, 2026 Feb 2, 2026 Jan 31, 2026 Jan 30, 2026 Jan 29, 2026 Jan 28, 2026 Jan 27, 2026 Jan 26, 2026 Jan 23, 2026 Jan 22, 2026 Jan 21, 2026 Jan 20, 2026 Jan 17, 2026 Jan 16, 2026 Jan 15, 2026 Jan 14, 2026 Jan 9, 2026 Jan 8, 2026 Jan 7, 2026 Jan 6, 2026 Dec 19, 2025 Dec 18, 2025 Dec 17, 2025 Dec 12, 2025 Dec 11, 2025 Dec 10, 2025 Dec 9, 2025 Dec 6, 2025 Dec 5, 2025 Dec 4, 2025 Dec 3, 2025 Dec 2, 2025 Dec 1, 2025 Nov 27, 2025 Nov 26, 2025 Nov 25, 2025 Nov 24, 2025 Nov 23, 2025 Nov 21, 2025 Nov 20, 2025 Nov 19, 2025 Nov 18, 2025 Nov 17, 2025 Nov 15, 2025 Nov 14, 2025 Nov 13, 2025 Nov 12, 2025 Nov 11, 2025 Nov 10, 2025 Nov 9, 2025 Nov 8, 2025 Nov 7, 2025 Nov 6, 2025 Nov 5, 2025 Nov 4, 2025 Nov 1, 2025 Oct 31, 2025 Oct 30, 2025 Oct 29, 2025 Oct 28, 2025 Oct 27, 2025 Oct 25, 2025 Oct 24, 2025 Oct 23, 2025 Oct 22, 2025 Oct 21, 2025 Oct 17, 2025 Oct 16, 2025 Oct 15, 2025 Oct 14, 2025 Oct 9, 2025 Oct 8, 2025 Oct 7, 2025 Sep 25, 2025 Sep 23, 2025 Sep 17, 2025 Sep 16, 2025 Sep 11, 2025 Sep 10, 2025 Sep 9, 2025 Sep 5, 2025 Sep 4, 2025 Sep 3, 2025 Sep 2, 2025 Sep 1, 2025 Aug 28, 2025 Aug 26, 2025 Aug 25, 2025 Aug 22, 2025 Aug 21, 2025 Aug 20, 2025 Aug 19, 2025 Aug 18, 2025 Aug 15, 2025 Aug 14, 2025 Aug 13, 2025 Aug 12, 2025 Aug 11, 2025 Aug 9, 2025 Aug 8, 2025 Aug 2, 2025 Aug 1, 2025 Jul 30, 2025 Jul 29, 2025 Jul 25, 2025
19 companies Today

Abbott Laboratories

ABT Q3 2025
Reported: 2025-10-16

Abbott Laboratories reported a robust 7.5% organic sales growth in Q3 2025, primarily driven by a strong performance in medical devices and established pharmaceuticals, despite a decline in COVID test sales.

Key takeaways
  • Earnings per share rose to $1.30, reflecting high single-digit growth year-over-year, excluding COVID test impacts.
  • New product launches contributed nearly $5 billion in sales this quarter, adding over 100 basis points to organic sales growth.
  • Medical Devices segment grew by 12.5%, led by solid performances in diabetes care and electrophysiology.
  • Established Pharmaceuticals experienced high single-digit growth, driven by strong contributions from core markets and therapeutic areas.
  • Strategic investments in nutrition products are set to leverage favorable consumer trends, evidenced by new launches in the adult nutrition segment.

ASML Holding N.V.

ASML Q3 2025
Reported: 2025-10-16

ASML Holding N.V. reported strong Q3 2025 results, with net sales of €7.5 billion and net income of €2.1 billion, bolstered by ongoing demand for advanced semiconductor technologies.

Key takeaways
  • Q3 net sales included €2 billion in installed base revenue and one High NA system recognition.
  • Gross margin for the quarter was 51.6%, in line with company guidance.
  • Net bookings for the quarter were €5.4 billion, with €3.6 billion attributed to extreme ultraviolet (EUV) systems.
  • Q4 revenue guidance is projected between €9.2 billion and €9.8 billion, anticipating strong seasonal demand.
  • ASML's partnership with Mistral AI, including an 11% equity stake, aims to enhance software capabilities and accelerate product development.

ASML Holding N.V.

ASML.AS Q3 2025
Reported: 2025-10-16

ASML Holding N.V. reported strong Q3 2025 results with net sales of €7.5 billion and net income of €2.1 billion, driven by robust demand in advanced logic and DRAM markets alongside a successful product roadmap execution.

Key takeaways
  • Net bookings reached €5.4 billion, including €3.6 billion for extreme ultraviolet (EUV) systems.
  • Guidance for Q4 2025 indicates revenue between €9.2 billion and €9.8 billion, projecting a full-year estimate of approximately €32.5 billion in net sales.
  • Advanced technology development continues, with successful launches of the XT260 high productivity scanner and significant progress in 3D integration solutions.
  • Strategic partnership established with Mistral AI, enhancing ASML's software capabilities and aligning with AI-driven market demands.
  • Anticipation of sustained net sales in 2026, primarily supported by evolving product mix dynamics and ongoing innovations.

Community

See what investors are trading, holding, and sharing

🌐
All
📈
Stock
📊
ETF
🏦
Mutual Fund
🪙
Crypto
💱
Forex
# Asset Price Community % Type Currency Sector
Loading...